Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Tectonic Therapeutic, Inc. (TECX) since 2018 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Tectonic Therapeutic, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1681087.
Total stock buying since 2018: $94,792,544.
Total stock sales since 2018: $11,629,207.
Total stock option exercises since 2018: $173,103.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 1,435,834 | $52,201,591 | 500,000 | $8,550,000 | 2,700 | $6,426 |
| 2024 | 1,116,635 | $12,527,447 | 0 | $0 | 148,586 | $13,090 |
| 2023 | 0 | $0 | 0 | $0 | 45,999 | $41,859 |
| 2022 | 0 | $0 | 0 | $0 | 142,013 | $58,651 |
| 2021 | 6,800 | $63,500 | 0 | $0 | 0 | $0 |
| 2020 | 0 | $0 | 89,400 | $2,437,493 | 100,000 | $41,300 |
| 2019 | 1,621,622 | $30,000,006 | 24,000 | $641,714 | 0 | $0 |
| 2018 | 0 | $0 | 0 | $0 | 12,942 | $11,777 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-04 | 641,923 | $10,853,089 | 500,000 | $8,550,000 | 0 | $0 |
| 2025-02 | 793,911 | $41,348,502 | 0 | $0 | 0 | $0 |
| 2025-01 | 0 | $0 | 0 | $0 | 2,700 | $6,426 |
| 2024-12 | 0 | $0 | 0 | $0 | 5,500 | $13,090 |
| 2024-10 | 300,000 | $10,077,000 | 0 | $0 | 0 | $0 |
| 2024-09 | 50,000 | $1,478,250 | 0 | $0 | 0 | $0 |
| 2024-05 | 766,635 | $972,197 | 0 | $0 | 0 | $0 |
| 2024-02 | 0 | $0 | 0 | $0 | 143,086 | $0 |
| 2023-01 | 0 | $0 | 0 | $0 | 45,999 | $41,859 |
| 2022-12 | 0 | $0 | 0 | $0 | 142,013 | $58,651 |
| 2021-07 | 4,800 | $40,080 | 0 | $0 | 0 | $0 |
| 2021-02 | 2,000 | $23,420 | 0 | $0 | 0 | $0 |
| 2020-12 | 0 | $0 | 0 | $0 | 100,000 | $41,300 |
| 2020-02 | 0 | $0 | 79,400 | $2,207,493 | 0 | $0 |
| 2020-01 | 0 | $0 | 10,000 | $230,000 | 0 | $0 |
| 2019-07 | 1,621,622 | $30,000,006 | 0 | $0 | 0 | $0 |
| 2019-04 | 0 | $0 | 24,000 | $641,714 | 0 | $0 |
| 2018-10 | 0 | $0 | 0 | $0 | 12,942 | $11,777 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-04-11 | Springer Timothy A | Buy | 63,184 | 16.31 | 1,030,531 |
| 2025-04-10 | Springer Timothy A | Buy | 53,950 | 16.73 | 902,583 |
| 2025-04-09 | Springer Timothy A | Buy | 24,789 | 14.93 | 369,975 |
| 2025-04-07 | Mcguire Terrance | Sale | 500,000 | 17.10 | 8,550,000 |
| 2025-04-07 | Springer Timothy A | Buy | 500,000 | 17.10 | 8,550,000 |
| 2025-02-05 | Lochner Daniel (Chief Financial Officer) | Buy | 4,617 | 54.14 | 249,964 |
| 2025-02-05 | Springer Timothy A | Buy | 789,294 | 52.07 | 41,098,538 |
| 2025-01-28 | Schwabish Marc (Chief Business Officer) | Option Ex | 2,700 | 2.38 | 6,426 |
| 2024-12-09 | Schwabish Marc (Chief Business Officer) | Option Ex | 2,000 | 2.38 | 4,760 |
| 2024-12-03 | Mcnamara Peter (Chief Scientific Officer) | Option Ex | 3,500 | 2.38 | 8,330 |
| 2024-10-22 | Springer Timothy A | Buy | 300,000 | 33.59 | 10,077,000 |
| 2024-09-26 | Springer Timothy A | Buy | 50,000 | 29.57 | 1,478,250 |
| 2024-05-14 | Leonard Braden Michael | Buy | 296,882 | 1.30 | 385,946 |
| 2024-05-13 | Leonard Braden Michael | Buy | 469,753 | 1.25 | 586,251 |
| 2024-02-01 | Golipour Azadeh (Chief Technology Officer) | Option Ex | 37,334 | .00 | 0 |
| 2024-02-01 | Ridha Essra (Chief Medical Officer) | Option Ex | 32,834 | .00 | 0 |
| 2024-02-01 | Ostrowski Erik (Interim CEO, President and CFO) | Option Ex | 40,084 | .00 | 0 |
| 2024-02-01 | Avruch Steven (Chief Legal Officer) | Option Ex | 32,834 | .00 | 0 |
| 2023-01-24 | Mackay Geoffrey (President & CEO) | Option Ex | 45,999 | .91 | 41,859 |
| 2022-12-23 | Mackay Geoffrey (President & CEO) | Option Ex | 142,013 | .41 | 58,651 |
| 2021-07-07 | Vickers Philip J. (Director) | Buy | 4,800 | 8.35 | 40,080 |
| 2021-02-17 | Donenberg Phillip B. (Director) | Buy | 2,000 | 11.71 | 23,420 |
| 2020-12-24 | Mackay Geoffrey (President & CEO) | Option Ex | 100,000 | .41 | 41,300 |
| 2020-02-12 | Mackay Geoffrey (See Remarks) | Sale | 1,400 | 29.07 | 40,692 |
| 2020-02-11 | Paige Christopher (Director) | Sale | 15,000 | 28.00 | 420,000 |
| 2020-02-11 | Mackay Geoffrey (See Remarks) | Sale | 63,000 | 27.73 | 1,746,801 |
| 2020-01-28 | Paige Christopher (Director) | Sale | 10,000 | 23.00 | 230,000 |
| 2019-07-19 | Atlas Venture Associates X, Llc (10% Owner) | Buy | 810,811 | 18.50 | 15,000,003 |
| 2019-07-19 | Booth Bruce (Director) | Buy | 810,811 | 18.50 | 15,000,003 |
| 2019-04-08 | Paige Christopher (Director) | Sale | 2,500 | 26.38 | 65,952 |
| 2019-04-08 | Mackay Geoffrey (See Remarks) | Sale | 698 | 27.07 | 18,893 |
| 2019-04-05 | Paige Christopher (Director) | Sale | 7,500 | 25.90 | 194,257 |
| 2019-04-05 | Mackay Geoffrey (See Remarks) | Sale | 13,302 | 27.26 | 362,612 |
| 2018-10-08 | Kreher Nerissa (Chief Medical Officer) | Option Ex | 2,942 | .91 | 2,677 |
| 2018-10-08 | Dorton Katina (Chief Financial Officer) | Option Ex | 10,000 | .91 | 9,100 |
Insider trading activities including stock purchases, stock sales, and option exercises of TECX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Tectonic Therapeutic, Inc. (symbol TECX, CIK number 1681087) see the Securities and Exchange Commission (SEC) website.